Exane Asset Management Decreases Stock Holdings in Eli Lilly and Company $LLY

Exane Asset Management lowered its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 97.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 100 shares of the company’s stock after selling 4,294 shares during the quarter. Eli Lilly and Company accounts for about 0.0% of Exane Asset Management’s portfolio, making the stock its 26th largest position. Exane Asset Management’s holdings in Eli Lilly and Company were worth $76,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Laurel Wealth Advisors LLC grew its position in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after acquiring an additional 11,537,661 shares in the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at approximately $8,827,714,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock worth $62,680,004,000 after purchasing an additional 1,183,038 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after purchasing an additional 564,736 shares during the period. Finally, Canada Pension Plan Investment Board increased its position in shares of Eli Lilly and Company by 87.2% during the 2nd quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after purchasing an additional 536,679 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors.

Eli Lilly and Company Trading Down 2.3%

LLY stock opened at $1,038.23 on Wednesday. The company has a market capitalization of $981.52 billion, a PE ratio of 50.79, a P/E/G ratio of 0.80 and a beta of 0.35. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The firm’s 50-day moving average is $1,058.15 and its 200 day moving average is $885.09. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The firm’s quarterly revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong commercial momentum from Lilly’s weight‑loss and diabetes franchise continues to underpin investor bullishness, supporting high revenue and EPS guidance. Up 36%, Is Eli Lilly Still a Buy?
• Positive Sentiment: Clinical and R&D advances — including completion of the pirtobrutinib Phase 1/2 study segment — add upside optionality in oncology/BTK space if later‑stage data hold up. Eli Lilly’s Pirtobrutinib Trial Completion Signals Next Phase in the BTK Inhibitor Race
• Positive Sentiment: Pipeline and strategic tech investment headlines (FDA Breakthrough designation for a candidate plus an AI partnership) support long‑term growth expectations beyond GLP‑1s. Eli Lilly (LLY) Oncology Pipeline and $1B Nvidia (NVDA) AI Partnership Signal Strong 2026 Growth
• Neutral Sentiment: Analyst pieces and stock‑watch coverage note Lilly’s heavy market interest and valuation questions — useful for framing risk/reward but not immediate catalysts. Eli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Marketing shifts (focus on “weight stigma”) reflect competitive positioning as GLP‑1 competition heats up; relevant for long‑term brand/market share but not an immediate earnings shock. Eli Lilly’s (LLY) New Marketing Focuses on ‘Weight Stigma’
• Negative Sentiment: The U.S. CMS added multiple Lilly branded drugs to the next cycle of the Medicare Drug Price Negotiation Program, increasing potential downward pressure on future pricing and margins for affected products (including the first Part B reimbursements). US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks
• Negative Sentiment: The American Hospital Association and other hospital groups are urging regulators to block Lilly’s new 340B claims‑data submission policy, creating regulatory/legal uncertainty and potential commercial/frictional headwinds with hospitals. AHA Urges HRSA to Stop Eli Lilly’s New Policy on 340B Hospitals From Going into Effect

Analyst Ratings Changes

A number of brokerages recently issued reports on LLY. Wolfe Research raised their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Guggenheim reduced their target price on shares of Eli Lilly and Company from $1,163.00 to $1,161.00 and set a “buy” rating on the stock in a research note on Tuesday, January 20th. Berenberg Bank raised their target price on shares of Eli Lilly and Company from $830.00 to $950.00 and gave the stock a “hold” rating in a report on Tuesday, December 2nd. Scotiabank began coverage on shares of Eli Lilly and Company in a report on Thursday, November 13th. They set a “sector outperform” rating and a $1,165.00 price target on the stock. Finally, Bank of America decreased their price objective on shares of Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a research note on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $1,173.91.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.